• About us
• Contact

Advertisement

Organisation › Details

Alligator Bioscience AB (Nasdaq Stockholm: ATORX)

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. *

 

	Start	2000-12-01 established
	Group	Alligator Bioscience (Group)
	Predecessor	University of Lund (Lund University)
	Industry	FIND® technology (Fragment INduced Diversity)
	Industry 2	mitazalimab (ADC-1013)
	Person	Norlén, Per (Alligator Bioscience –202103 CEO)
	Person 2	Benson, Peter (Sunstone Capital 200705– Managing Partner Life Science Ventures)
	Region	Lund
	Country	Sweden
	City	223 81 Lund
	Tel	+46-46-286-4280
		Address record changed: 2020-12-02
Basic data	Employees	C: 51 to 100 (2019-12-31)
	Currency	SEK
	Annual sales	4,352,000 (sales, net, consolidated (2020) 2020-12-31)
	Profit	-143,296,000 (2020-12-31)
	Cash	103,342,000 (2020-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Alligator Bioscience (Group)

• [1] Alligator Bioscience AB. (3/22/23). "Press Release: Alligator Intends to Carry Out a 91 Percent Secured Rights Issue of Units of Approximately SEK 199 Million [Not for US, AU, et al.]"....
• [2] Alligator Bioscience AB. (4/15/21). "Press Release: Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy". Lund....
• [3] Alligator Bioscience AB. (3/18/21). "Press Release: Alligator Bioscience Appoints Søren Bregenholt as New CEO". Lund....
• [4] Alligator Bioscience AB. (3/5/20). "Press Release: Alligator Bioscience Appoints Andreas Johannesson as Interim Chief Financial Officer". Lund....
• [5] Alligator Bioscience AB. (2/12/20). "Press Release: Alligator Bioscience AB Year-end Report January-December 2019"....
• [6] Alligator Bioscience AB. (12/17/19). "Press Release: First Patient Dosed with ATOR-1017 Developed for Metastasized Cancer". Lund....
• [7] Alligator Bioscience AB. (12/11/19). "Press Release: CFO Per-Olof Schrewelius Leaves Alligator Bioscience". Lund....
• [8] Alligator Bioscience AB. (11/29/19). "Press Release: Alligator Bioscience AB Appoints Chief Operating Officer". Lund....
• [9] Alligator Bioscience AB. (8/20/19). "Press Release: Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.". Lund....
• [10] Alligator Bioscience AB. (7/31/19). "Press Release: Alligator Bioscience Regains Global Rights from Janssen to CD40 Agonistic Antibody, ADC-1013 (JNJ-64457107)". Lund....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.